stockrow
Friday 6 November 2026
Export RPRX’s income statement to Excel — free account
Royalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
67.28
0.29
−0.43%
Follow RPRX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 5 | 6 | — |
| 7.69% | 8.38% | 8.42% | 0.00% | ||
| 4.07% | 4.42% | 4.26% | 0.00% | ||
ROIC |
5.41% | 5.43% | 5.28% | 5.24% | |
Return on Tangible Assets |
4.51% | 4.74% | 4.69% | 0.00% | |
Average Days of Receivables |
4.50 | 4.11 | 4.53 | 0.00 | |
Free Cash Flow per Share |
5.79 | 2.74 | 2.94 | 6.64 | |
Free Cash Flow |
2,489.82 | 1,195.57 | 1,310.08 | 2,959.92 | |
Capital Expenditures |
— | (1,416.41) | (1,666.37) | — | |
| Other line items | |||||
Cash ROIC |
12.90% | 6.13% | 6.69% | 15.64% | |
Accounts Receivable Turnover |
84.52 | 95.15 | 85.65 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
19.01% | 18.08% | 9.41% | 9.60% | |
Selling, General and Administrative Expense of Revenue |
24.11% | 25.50% | 23.83% | 24.29% | |
Share Based Compensation of Revenue |
12.19% | 16.86% | 16.86% | 17.57% | |
Interest Coverage |
5.07 | 4.73 | 4.19 | 4.02 | |
Operating CF/Net income |
3.23 | 3.16 | 3.67 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | (39.29) | (46.64) | — | |
Revenue per Share |
5.53 | 5.59 | 5.70 | 5.87 | |
Operating CF per Share |
5.79 | 5.98 | 6.69 | 6.64 | |
Capex per Share |
0.00 | (3.24) | (3.74) | 0.00 | |
Capex to Sales |
0.00 | 0.58 | 0.66 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026